Overview Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363) Status: Completed Trial end date: 2009-03-01 Target enrollment: Participant gender: Summary Evaluation of treatment in participants with mild asthma. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.